Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

New England Journal of Medicine

Volumn 352, Issue 24, 2005, Pages 2487-2498

  Richardson, Paul G ^a   Sonneveld, Pieter ^b   Schuster, Michael W ^c   Irwin, David ^d   Stadtmauer, Edward A ^e   Facon, Thierry ^f   Harousseau, Jean Luc ^g   Ben Yehuda, Dina ^h   Lonial, Sagar ⁱ   Goldschmidt, Hartmut ^j   Reece, Donna ^k   San Miguel, Jesus F ^l   Bladé, Joan ^m   Boccadoro, Mario ⁿ   Cavenagh, Jamie ^o   Dalton, William S ^p   Boral, Anthony L ^q   Esseltine, Dixie L ^q   Porter, Jane B ^q   Schenkein, David ^q   Anderson, Kenneth C ^a   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Alta Bates Cancer Center   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

ⁱ EMORY UNIVERSITY   (United States)

^j UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^m INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁿ UNIVERSITY OF TURIN   (Italy)

^o ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^p H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^q MILLENNIUM PHARMACEUTICALS INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; HAZARD ASSESSMENT; HEART FAILURE; HERPES ZOSTER; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPENIA; PATIENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RESPIRATORY FAILURE; SEPSIS; SPINAL CORD COMPRESSION; SUBDURAL HEMATOMA; SURVIVAL; THROMBOCYTOPENIA; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; FOLLOW UP; HEMATOLOGIC DISEASE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; RECURRENT DISEASE; SURVIVAL RATE; THROMBOCYTE COUNT;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DEXAMETHASONE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PLATELET COUNT; PROTEASE INHIBITORS; PYRAZINES; RECURRENCE; SURVIVAL RATE;

EID: 20444433230     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa043445     Document Type: Article

References (40)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Attal M, Harousseau J-L, Stoppa A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
3. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
4. Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293-304.
5. Alexanian R, Barlogie B, Dixon D. Highdose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11.
6. Friedenberg WR, Kyle RA, Knospe WH, Bennett JM, Tsiatis AA, Oken MM. Highdose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991;36:171-5.
7. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-90.
8. Sonneveld P, Suciu S, Weijermans P, et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 2001;115:895-902.
9. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
10. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4.
11. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374-9.
12. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
13. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
14. Richardson PG, Barlogie B, Berenson J, et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: an update with additional followup. Hematol J 2004;5:Suppl 2:S103-S104. abstract.
15. Bladé J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23.
16. Calhoun EA, Fishman A, Roland PY, Lurain J, Chang C-H, Cella D. Validity and selective sensitivity of the FACT/GOG-Ntx. Proc Am Soc Clin Oncol 2000;19:446a. abstract.
17. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
18. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-56.
19. Alexanian R, Weber D, Anagnostopoulos A, Delasalle K, Wang M, Rankin K. Thalidomide with or without dexamethasone for refractory relapsing multiple myeloma. Semin Hematol 2000;40:Suppl 4:3-7.
20. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
21. Durie BGM, Stepan DE. Efficacy of low dose thalidomide (T) in multiple myeloma. Blood 1999;94:316. abstract.
22. Grosbois B, Bellisant E, Moreau P. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM): a prospective study of 120 patients. Blood 2001;98:689. abstract.
23. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al. Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001;86:404-8.
24. Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
25. Rajkumar SV, Fonseca R, Dispenzieri A, et al. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma (MM) with laboratory correlative studies. Blood 2000;96:168a. abstract.
26. Raza SN, Veksler YST, Li Z, et al. Durable response to thalidomide in relapsed/refractory multiple myeloma (MM). Blood 2000;96:168a-169a. abstract.
27. Tosi P, Zamagni E, Cellini C, et al. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002;87:408-14.
28. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9.
29. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002;3:185-92.
30. Neben K, Moehler T, Benner A, et al. Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002;8:3377-82.
31. Barlogie B, Alexanian R. Therapy of primary resistant and relapsed multiple myeloma. Onkologie 1986;9:210-4.
32. Mineur P, Menard JF, Le Loet X, et al. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). Br J Haematol 1998;103:512-7.
33. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma: an Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995;18:475-80.
34. Browman GP, Belch A, Skillings J, et al. Modified Adriamycin-vincristine- dexamethasone (m-VAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. Br J Haematol 1992;82:555-9.
35. Niesvizky R, Bergsagel PL, Pearse RN, et al. The addition of clarithromycin improves response to dexamethasone in chemotherapy naïve multiple myeloma patients. Proc Am Soc Clin Oncol 2003;22:582.
36. Rajkumar SV, Blood E, Vesole DH, et al. A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:560s. abstract.
37. Kumar SV, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004;79:867-74.
38. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
39. Lonial S, Waller EK, Richardson PG, et al. Evaluation of the severity and risk of thrombocytopenia with bortezomib therapy in relapsed and refractory multiple myeloma. J Hematol 2004;5:Suppl 2:S130-S131. abstract.
40. Richardson PG, Briemberg H, Jagannath S, et al. Peripheral neuropathy following bortezomib (VELCADE, formerly PS-341) therapy in patients with advanced multiple myeloma (MM): characterization and reversibility. Blood 2003;102:149a. abstract.